FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033424432> ?p ?o ?g. }

• W3033424432 endingPage "AB82" @default.
• W3033424432 startingPage "AB81" @default.
• W3033424432 abstract "Upper gastrointestinal bleeding (UGIB) is a leading cause of morbidity associated with a 2-17% mortality in the USA and UK despite advances in endoscopic therapy. Hemospray (Cook Medical, North Carolina, USA) is an endoscopic haemostatic powder for GI bleeding. The aim of this study was to look at outcomes in patients with non-variceal UGIBs secondary to all causes treated with Hemospray in 16 centres. Secondary outcomes included re-bleeding, 30-day mortality and disease specific outcomes. Data was collected prospectively (January 2016- November 2019) from 16 centres in the USA, UK, Germany, France and Spain. Hemospray was used during emergency endoscopy for a variety of causes of UGIB’s as a monotherapy, dual therapy with standard haemostatic techniques or rescue therapy once standard methods have failed. Haemostasis was defined as cessation of bleeding within 5 minutes of hemospray application. Rebleeding was defined as a sustained drop in Hb (>2g/l), haematemesis or melaena with haemodynamic instability following index endoscopy. 512 patients with non-variceal UGIBs were recruited (343 male, 169 female). The most common cause of UGIB was peptic ulcers (236/512, 46%), followed by Malignancy (96/512, 19%), post procedure (73/512, 14%), Oesophagitis/Gastritis/Doudenitis (20/512, 4%), Mallery weiss tear (17/512, 3%), Angiodysplasia/Douelifouy (12/512, 2%). (Table 1). Overall immediate haemostasis was achieved in 473/512 (92%) patients. Median Blatchford score was 11 (IQR, 8-14), median Rockall score was 7 (IQR, 6-8). Re-bleeding occurred in 59/404 (15%) patients. There was an overall 7-day mortality (all cause) of 9% (42/444), 30-day mortality (all cause) was 19% (85/444). The highest haemostasis rates were in the Hemospray monotherapy group (95%), followed by combination therapy (91%) then rescue therapy (90%). (Table 2). 39 patients did not achieve immediate haemostasis following Hemospray treatment. The majority of these patients (69%) had peptic ulcer bleeds. 14/39 (36%) of these patients had CT embolization, 7 /39 (18%) were managed conservatively and 3/39 (8%) had surgery. There were high immediate haemostasis rates following the treatment of non-variceal UGIBs of all causes with Hemospray when it was used as a monotherapy, combination therapy or rescue therapy. The better outcomes were when Hemospray was used in UGIB’s post endotherapy, secondary to malignancy and in Angiodysplasia. The results from this registry show that Hemospray can play a vital role as an endoscopic haemostatic method in UGIBs particularly in malignancies where it can bridge towards surgery or chemoradiotherapy, and post endotherapy where it can provide definitive haemostasis. In both cohorts there was low re-bleed rates.View Large Image Figure ViewerDownload Hi-res image Download (PPT)" @default.
• W3033424432 created "2020-06-12" @default.
• W3033424432 creator A5001648753 @default.
• W3033424432 creator A5006986778 @default.
• W3033424432 creator A5012353557 @default.
• W3033424432 creator A5025381238 @default.
• W3033424432 creator A5030911026 @default.
• W3033424432 creator A5033576050 @default.
• W3033424432 creator A5034763400 @default.
• W3033424432 creator A5042843181 @default.
• W3033424432 creator A5047534120 @default.
• W3033424432 creator A5053444208 @default.
• W3033424432 creator A5060915537 @default.
• W3033424432 creator A5066665388 @default.
• W3033424432 creator A5067749370 @default.
• W3033424432 creator A5072581119 @default.
• W3033424432 creator A5075497113 @default.
• W3033424432 creator A5075802978 @default.
• W3033424432 creator A5079464849 @default.
• W3033424432 creator A5080066400 @default.
• W3033424432 creator A5080096604 @default.
• W3033424432 creator A5081395677 @default.
• W3033424432 creator A5083810588 @default.
• W3033424432 creator A5083931043 @default.
• W3033424432 creator A5085849508 @default.
• W3033424432 creator A5088446357 @default.
• W3033424432 creator A5089888467 @default.
• W3033424432 creator A5090473831 @default.
• W3033424432 creator A5091268069 @default.
• W3033424432 date "2020-06-01" @default.
• W3033424432 modified "2023-10-03" @default.
• W3033424432 title "963 HEMOSPRAY IN THE TREATMENT OF NON-VARICEAL UPPER GASTROINTESTINAL BLEEDS: OUTCOMES FROM THE FIRST 500 PATIENTS FROM THE INTERNATIONAL HEMOSPRAY REGISTRY" @default.
• W3033424432 doi "https://doi.org/10.1016/j.gie.2020.03.624" @default.
• W3033424432 hasPublicationYear "2020" @default.
• W3033424432 type Work @default.
• W3033424432 sameAs 3033424432 @default.
• W3033424432 citedByCount "0" @default.
• W3033424432 crossrefType "journal-article" @default.
• W3033424432 hasAuthorship W3033424432A5001648753 @default.
• W3033424432 hasAuthorship W3033424432A5006986778 @default.
• W3033424432 hasAuthorship W3033424432A5012353557 @default.
• W3033424432 hasAuthorship W3033424432A5025381238 @default.
• W3033424432 hasAuthorship W3033424432A5030911026 @default.
• W3033424432 hasAuthorship W3033424432A5033576050 @default.
• W3033424432 hasAuthorship W3033424432A5034763400 @default.
• W3033424432 hasAuthorship W3033424432A5042843181 @default.
• W3033424432 hasAuthorship W3033424432A5047534120 @default.
• W3033424432 hasAuthorship W3033424432A5053444208 @default.
• W3033424432 hasAuthorship W3033424432A5060915537 @default.
• W3033424432 hasAuthorship W3033424432A5066665388 @default.
• W3033424432 hasAuthorship W3033424432A5067749370 @default.
• W3033424432 hasAuthorship W3033424432A5072581119 @default.
• W3033424432 hasAuthorship W3033424432A5075497113 @default.
• W3033424432 hasAuthorship W3033424432A5075802978 @default.
• W3033424432 hasAuthorship W3033424432A5079464849 @default.
• W3033424432 hasAuthorship W3033424432A5080066400 @default.
• W3033424432 hasAuthorship W3033424432A5080096604 @default.
• W3033424432 hasAuthorship W3033424432A5081395677 @default.
• W3033424432 hasAuthorship W3033424432A5083810588 @default.
• W3033424432 hasAuthorship W3033424432A5083931043 @default.
• W3033424432 hasAuthorship W3033424432A5085849508 @default.
• W3033424432 hasAuthorship W3033424432A5088446357 @default.
• W3033424432 hasAuthorship W3033424432A5089888467 @default.
• W3033424432 hasAuthorship W3033424432A5090473831 @default.
• W3033424432 hasAuthorship W3033424432A5091268069 @default.
• W3033424432 hasBestOaLocation W30334244321 @default.
• W3033424432 hasConcept C126322002 @default.
• W3033424432 hasConcept C141071460 @default.
• W3033424432 hasConcept C2776345487 @default.
• W3033424432 hasConcept C2778451229 @default.
• W3033424432 hasConcept C2910135376 @default.
• W3033424432 hasConcept C71924100 @default.
• W3033424432 hasConceptScore W3033424432C126322002 @default.
• W3033424432 hasConceptScore W3033424432C141071460 @default.
• W3033424432 hasConceptScore W3033424432C2776345487 @default.
• W3033424432 hasConceptScore W3033424432C2778451229 @default.
• W3033424432 hasConceptScore W3033424432C2910135376 @default.
• W3033424432 hasConceptScore W3033424432C71924100 @default.
• W3033424432 hasIssue "6" @default.
• W3033424432 hasLocation W30334244321 @default.
• W3033424432 hasOpenAccess W3033424432 @default.
• W3033424432 hasPrimaryLocation W30334244321 @default.
• W3033424432 hasRelatedWork W166759132 @default.
• W3033424432 hasRelatedWork W2003360504 @default.
• W3033424432 hasRelatedWork W2084415259 @default.
• W3033424432 hasRelatedWork W2111489129 @default.
• W3033424432 hasRelatedWork W2371649181 @default.
• W3033424432 hasRelatedWork W2393782840 @default.
• W3033424432 hasRelatedWork W2411430163 @default.
• W3033424432 hasRelatedWork W2413394245 @default.
• W3033424432 hasRelatedWork W2911667836 @default.
• W3033424432 hasRelatedWork W4290250993 @default.
• W3033424432 hasVolume "91" @default.
• W3033424432 isParatext "false" @default.
• W3033424432 isRetracted "false" @default.
• W3033424432 magId "3033424432" @default.
• W3033424432 workType "article" @default.